SCHEMBL3372970

SCHEMBL3372970

O=C(NCc1ccccc1)c1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.58
HPGD P15428 2/20 0.51
POLB P06746 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
EGLN1 Q9GZT9 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HRH4 Q9H3N8 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
NAMPT P43490 1/20 0.50
IDO1 P14902 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NHERF1 O14745 1/20 0.49
TP53 P04637 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
GABRP O00591 1/20 0.47
GABRD O14764 1/20 0.47
GABRA1 P14867 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30642955 0.87 CNR2 (0.53) CNR2HPGDPOLBTDP1EGLN1
SCHEMBL29086821 0.87 CNR2 (0.53) CNR2HPGDPOLBTDP1EGLN1
SCHEMBL6016962 0.84 HDAC2 (0.65) CNR2POLBHDAC3HDAC1HDAC2
SCHEMBL25768258 0.82 HRH4 (0.57) EGLN1HRH4HRH3TP53SMN1; SMN2
SCHEMBL30912925 0.81 SMN1; SMN2 (0.50) CNR2POLBTDP1MEN1KMT2A
SCHEMBL6531634 0.78 SMN1; SMN2 (0.63) POLBKMT2ASMN1; SMN2KDM4E
SCHEMBL3673592 0.77 MMP13 (0.65) CNR2HPGDPOLBTDP1MEN1
SCHEMBL24754421 0.77 ALOX15 (0.52) HPGDPOLBTDP1EGLN1HRH4
SCHEMBL18766925 0.77 NHERF1 (0.79) HDAC3HDAC1HDAC2HRH4HRH3
SCHEMBL30912938 0.77 EGLN1 (0.53) CNR2HPGDEGLN1HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636216-B1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2010-07-21 EP disclosed
US-7741341-B2 Benzimidazole-derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-06-22 US disclosed
EP-1636216-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS Sanofi-Aventis Deutschland GmbH (DE) 2006-03-22 EP disclosed
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-01-13 US disclosed
WO-2004101553-A1 BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009829-A1 Benzimidazole-derivatives as factor Xa inhibitors F12, F11, F5 CNR2 1506/4885HPGD 1564/4885POLB 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.